Sorrento Therapeutics, Inc (NASDAQ:SRNE) achieved significant progress in developing COVISHIELD using Mount Sinai’s IP (the Icahn School of Medicine at Mount Sinai).
Sorrento utilized a license for IP developed by a team of scientists at Mount Sinai to develop an innovative formulation to neutralize the effects of SARS-CoV-2.
Inks an exclusive pact
The company entered an exclusive pact with Mount Sinai to utilize the antibodies that can neutralize the properties of the SARS-CoV-2 virus. As per the terms of the deal, Mount Sinai and Sorrento can collaborate to develop HMA (humanized monoclonal antibodies) for other therapeutic applications.
COVISHIELD comprises two monoclonal antibodies that are developed to get protection from emerging variants or existing SARS-CoV-2.
Sorrento developed monoclonal antibody combinations considering the early days of pandemic and emerging variants of the virus from across the world. It can protect against the coronavirus variants like those found in Brazil/ Japan, South Africa, and the UK.
Positive findings from the laboratory tests will support in FDA evaluation of its COVISHIELD and future development efforts. COVISHIELD is a result of using the development resources and discovery efforts of Sorrento together with Mount Sinai’s IP.
COVISHIELD protects from emerging and existing COVID-19
Sorrento is developing COVISHIELD to provide a rapid means for people to safeguard from pandemic threat pathogens and the prevailing/ emerging coronavirus variants.
Henry Ji, CEO of Sorrento, said the company is excited with the antibody candidates developed so far to contain the spread of coronavirus and provide protection against coronavirus.
The Sorrento team is committed to quickly bringing up a cocktail to protect from the upcoming and existing coronavirus variants. Sorrento expects to collaborate with Mount Sinai to develop anti-cancer and anti-viral therapeutics.
COF to commence clinical trial of Socazolimab
China Oncology Focus Limited (COF) said it received clearance to commence the phase 2 clinical study of Socazolimab, for which a license is obtained from Sorrento.
COF will conduct a double-blinded, randomized, and multicenter trial of Socazolimab in combination with chemotherapy to cure small cell lung cancer. It is an associate of Lee’s Pharmaceutical Holdings Limited.
In phase 1b clinical trials, Socazolimab showed a promising safety profile and efficacy in patients with small lung cancer when treated in combination with etoposide and carboplatin.
Sundial Growers Inc (NASDAQ:SNDL) Inks An Equity Sale Accord With ATB Capital Markets And Canaccord Genuity To Raise Maximum Of $800 Million: Reports $13.9 Million In Revenues In Q4 2020
Post Views: 248 Sundial Growers Inc (NASDAQ:SNDL) inked a stock sale agreement with ATB Capital Markets and Canaccord Genuity agents....
High Tide Inc (OTCMKTS:HITIF) Posts Impressive Growth Of 17% In Revenues In Q1 2021
Post Views: 582 High Tide Inc (OTCMKTS:HITIF) reported revenues of $38.3 million (up 179% YoY) in Q1 2021. It included...
Heritage Cannabis Holdings Corp (OTCMKTS:HERTF) Reports CAD 1.827 Million Revenues In Q1 2021
Post Views: 278 Heritage Cannabis Holdings Corp (OTCMKTS:HERTF) reported revenues of CAD 1.827 million (down 54.41% YoY) in Q1 2021....
Cresco Labs Inc (OTCMKTS:CRLBF) Reports Revenues Of $162.3 Million In Q4 2020: Adjusted EBITDA Increases 8% To $50 Million in Q4 2020
Post Views: 305 Cresco Labs Inc (OTCMKTS:CRLBF) reported a growth of 6% QoQ to $162.3 million in Q4 2020. Its...
Tauriga Sciences Inc (OTCMKTS:TAUG) Inks A Pact With Coalition Technologies To Improve SEO Metrics: Converts US PPA To Non US PPA
Post Views: 330 Tauriga Sciences Inc (OTCMKTS:TAUG) signed an agreement with Coalition Technologies to enhance its SEO (search engine optimization)...
Medipharm Labs Corporation (OTCMKTS:MEDIF) Expands Its Innovative Branded Products Line With Launch Of New Formulations
Post Views: 366 Medipharm Labs Corporation (OTCMKTS:MEDIF) has announced the expansion of its innovative Pharma-quality family branded products with the...